• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401
APEIRON to utilize MaxCyte's ExPERT® platform for siRNA-based cell therapy APN401 targeting solid tumors and secures manufacturing for upcoming clinical trials VIENNA and GAITHERSBURG, Md., July 8, 2020 -- (Healthcare Sales & Marketing Network) -- ... Biopharmaceuticals, Oncology, Licensing MaxCyte, APEIRON Biologics, cell therapy
Source: HSMN NewsFeed - July 8, 2020 Category: Pharmaceuticals Source Type: news

Sirnaomics' Leading siRNA Therapeutic Candidate, STP705, Granted Orphan Designation for Treatment of Cholangiocarcinoma
GAITHERSBURG, Md., Dec. 6, 2017 -- (Healthcare Sales & Marketing Network) -- Sirnaomics, Inc. (www.sirnaomics.com), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the Office of Orphan Product De... Biopharmaceuticals, Oncology, FDA Sirnaomics, Cholangiocarcinoma
Source: HSMN NewsFeed - December 6, 2017 Category: Pharmaceuticals Source Type: news

Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with Nitto Denko for Targeted siRNA Therapy in Advanced Non-alcoholic Steatohepatitis (NASH) and Cirrhosis Due to NASH
NEW YORK & OSAKA, Japan--(Healthcare Sales & Marketing Network)--Bristol-Myers Squibb Company (BMY) and Nitto Denko Corporation (Nitto) (6988:Tokyo) today announced the companies have entered into an agreement granting Bristol-Myers Squibb exclusive worldw... Biopharmaceuticals, Licensing Bristol-Myers Squibb, Nitto Denko
Source: HSMN NewsFeed - November 10, 2016 Category: Pharmaceuticals Source Type: news